Clinical Trials Directory

Trials / Unknown

UnknownNCT02570776

UBT as a Diagnostic Tool for HP Prevalance

Prevalence of Helicobacter Pylori Infection in Dyspeptic Adults and Validation of C14 Urea Breath Test (UBT) as a Diagnostic Tool for Helicobacter Pylori Infection in Pakistani Population

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
National Institute of Liver & GI Diseases, Pakistan · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The prevalence of H. pylori infection in Pakistan is unknown and investigators want to assess it in dyspeptic patients utilizing UBT. At the same time investigators want to validate UBT sensitivity and specificity in Pakistani patients

Detailed description

The non-invasive methods for the diagnosis of Hp are the Urea Breath Test (UBT) and serological tests. The serological tests includes ELISA test in serum for Hp antibody and in stool for Hp antigen. Serum ELISA Hp antibody is not sensitive for showing active infection and the titres do not decrease even after successful eradication. Serology test cannot be used for those who have previously been treated for Hp, as the decline in titre of Hp antibodies is too slow to be of practical use. The stool Hp antigen detection test is more sensitive and specific as it detects bacterial antigens which will only be positive in the presence of Hp. However, it is cumbersome to collect stool and laboratory services are required. The C14 Urea Breath Test (UBT) is an office based test with sensitivity and specificity comparable to that of the stool antigen test. The diagnostic validity of these tests depends on the prevalence of H pylori infection. A higher prevalence would be associated with higher sensitivity and lower specificity. The safety profile of the urea breath test is very favourable, and no major side effects are associated with it. The aims of this study are to estimate H pylori prevalence in Pakistan among the adult dyspeptic population and to validate the sensitivity and specificity UBT in our population

Conditions

Timeline

Start date
2013-12-01
Primary completion
2015-12-01
Completion
2016-02-01
First posted
2015-10-07
Last updated
2015-10-07

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT02570776. Inclusion in this directory is not an endorsement.

UBT as a Diagnostic Tool for HP Prevalance (NCT02570776) · Clinical Trials Directory